

Day : Monday  
Date: 9/25/2006

Time: 11:06:39


**PALM INTRANET**

## Inventor Name Search Result

Your Search was:

Last Name = WON

First Name = CHEE-YOUB

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<a href="#">09531451</a>	<a href="#">6388047</a>	150	03/20/2000	HYDROGEL-FORMING SYSTEM WITH HYDROPHOBIC AND HYDROPHILIC COMPONENTS	WON, CHEE-YOUB
<a href="#">09743790</a>	<a href="#">6476204</a>	150	01/19/2001	DEXTRAN-MALEIC ACID MONOESTERS AND HYDROGELS BASED THEREON	WON, CHEE-YOUB
<a href="#">10096435</a>	<a href="#">6583219</a>	150	03/13/2002	HYDROGEL-FORMING SYSTEM WITH HYDROPHOBIC AND HYDROPHILIC COMPONENTS	WON, CHEE-YOUB
<a href="#">10143572</a>	<a href="#">6716445</a>	150	05/13/2002	HYDROGEL ENTRAPPING THERAPEUTIC AGENT AND STENT WITH COATING COMPRISING THIS	WON, CHEE-YOUB
<a href="#">10369676</a>	<a href="#">6709668</a>	150	02/21/2003	HYDROGEL-FORMING SYSTEM WITH HYDROPHOBIC AND HYDROPHILIC COMPONENTS	WON, CHEE-YOUB
<a href="#">10623873</a>	<a href="#">7049415</a>	150	07/21/2003	PEGYLATED T20 POLYPEPTIDE	WON, CHEE-YOUB
<a href="#">10623978</a>	Not Issued	71	07/21/2003	Polyethylene glycol aldehydes	WON, CHEE-YOUB
<a href="#">10625033</a>	Not Issued	89	07/22/2003	Polyalkylene glycol acid additives	WON, CHEE-YOUB
<a href="#">10625103</a>	<a href="#">7084261</a>	150	07/22/2003	PEGYLATED T1249 POLYPEPTIDE	WON, CHEE-YOUB
<a href="#">10733291</a>	<a href="#">6916857</a>	150	12/12/2003	HYDROGEL-FORMING SYSTEM WITH	WON, CHEE-YOUB

				HYDROPHOBIC AND HYDROPHILIC COMPONENTS	
<u>10762256</u>	<u>6905700</u>	150	01/23/2004	HYDROGEL ENTRAPPING THERAPEUTIC AGENT AND STENT WITH COATING COMPRISING THIS	WON, CHEE-YOUB
<u>11037011</u>	Not Issued	93	01/19/2005	HYDROGEL ENTRAPPING THERAPEUTIC AGENT AND STENT WITH COATING COMPRISING THIS	WON, CHEE-YOUB
<u>11386876</u>	Not Issued	30	03/22/2006	Polyalkylene glycol acid additives	WON, CHEE-YOUB
<u>60128803</u>	Not Issued	159	04/12/1999	HYDROGEL-FORMING SYSTEM WITH HYDROPHOBIC AND HYDROPHILIC COMPONENTS	WON, CHEE-YOUB
<u>60398137</u>	Not Issued	159	07/24/2002	Polyalkylene glycol acid additives	WON, CHEE-YOUB
<u>60398190</u>	Not Issued	159	07/24/2002	Pegylated T1249 polypeptide	WON, CHEE-YOUB
<u>60398195</u>	Not Issued	159	07/24/2002	Pegylated T20 polypeptide	WON, CHEE-YOUB
<u>60398196</u>	Not Issued	159	07/24/2002	Polyethylene glycol aldehydes	WON, CHEE-YOUB
<u>60439213</u>	Not Issued	159	01/10/2003	Pegylated T1249 polypeptide	WON, CHEE-YOUB

Inventor Search Completed: No Records to Display.

<b>Search Another: Inventor</b>	<b>Last Name</b>	<b>First Name</b>	<input type="button" value="Search"/>
	<input type="text" value="Won"/>	<input type="text" value="Chee-Youb"/>	

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:08:44 ON 25 SEP 2006

=> file pnttext

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'EPFULL' ENTERED AT 11:09:00 ON 25 SEP 2006

COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

FILE 'FRFULL' ENTERED AT 11:09:00 ON 25 SEP 2006

COPYRIGHT (C) 2006 Univentio

FILE 'GBFULL' ENTERED AT 11:09:00 ON 25 SEP 2006

COPYRIGHT (C) 2006 Univentio

FILE 'PATDPAFULL' ENTERED AT 11:09:00 ON 25 SEP 2006

COPYRIGHT (C) 2006 DPMA

FILE 'PCTFULL' ENTERED AT 11:09:00 ON 25 SEP 2006

COPYRIGHT (C) 2006 Univentio

FILE 'RDISCLOSURE' ENTERED AT 11:09:00 ON 25 SEP 2006

COPYRIGHT (C) 2006 Kenneth Mason Publications Ltd.

FILE 'USPATFULL' ENTERED AT 11:09:00 ON 25 SEP 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:09:00 ON 25 SEP 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s polyethylene glycol aldehyde#

L1 80 POLYETHYLENE GLYCOL ALDEHYDE#

=> s l1 and -NH-

L2 55 L1 AND -NH-

=> S L2 AND COMPOUND#

L3 52 L2 AND COMPOUND#

=> s l3 and cap?

L4 43 L3 AND CAP?

=> d l4 1-43

L4 ANSWER 1 OF 43 EPPFULL COPYRIGHT 2006 EPO/FIZ KA on STN

AN 2004:19342 EPPFULL UP 20050720

DUPD 20050720 DUPW 200529

TIEN Keratinocyte growth factor-2 products.

TIFR Produits a base du facteur de croissance 2 des keratinocytes.

TIDE Produkte des Keratinocyten-Wachstumsfaktors 2.

IN Nahri, Linda Owens, 2890 North Los Cedros Circle, Camarillo CA 93012, US;

Osslund, Timothy D., 475 Vista Montana, Camarillo CA 93012, US

PA Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US

PAN 2570213

AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietat, Maximilianstrasse 58, 80538 Muenchen, DE

AGN 100721

DT Patent

LAF English

LA English  
 LAP English  
 TL German; English; French  
 PIT EPA1 Application published with search report  
 PI EP 1473366 A1 20041103  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV RO SI  
 AI EP 2004-7578 A 19971015  
 RLI EP 1997-910119 19980423 EP 935652 Parent Application  
 PRAI US 1996-28493P P 19961015  
 US 1996-32781P P 19961206  
 US 1996-33046P P 19961211  
 IC.VER 7  
 ICM C12N015-12  
 ICS C12N015-62; C07K014-50; A61K038-18  
  
 L4 ANSWER 2 OF 43 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN  
  
 AN 2004:4702 EPFULL UP 20050810  
 DUPD 20050810 DUPW 200532  
 TIEN Uses of keratinocyte growth factor-2.  
 TIFR Utilisation du facteur de croissance des keratinocytes -2.  
 TIDE Verwendung von keratinocyte growth factor-2.  
 IN Lacey, David L., 614 Paseo Vista, Thousand Oaks, CA 91320, US;  
 Ulich, Thomas R., 13068 Lexington Hills Drive, Camarillo, CA 93012, US;  
 Danilenko, Dimitry M., 13082 Rancho Vista Court, Camarillo, CA 93012,  
 US;  
 Farrell, Catherine L., 29441 Mulholland Hwy., Agoura, California 91301,  
 US  
 PA Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US  
 PAN 2570213  
 AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietat,  
 Maximilianstrasse 58, 80538 Muenchen, DE  
 AGN 100721  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPA1 Application published with search report  
 PI EP 1452205 A1 20040901  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV RO SI  
 AI EP 2004-3545 A 19971015  
 RLI EP 1997-913676 19980423 EP 941110 Parent Application  
 PRAI US 1996-28495P P 19961015  
 US 1996-32253P P 19961206  
 US 1996-33457P P 19961210  
 IC.VER 7  
 ICM A61P017-02  
  
 L4 ANSWER 3 OF 43 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN  
  
 AN 2003:16425 EPFULL UP 20050223  
 DUPD 20050223 DUPW 200508  
 TIEN Combination therapy using a TNF binding protein for treating  
 TNF-mediated diseases.  
 TIFR Therapie combinatoire utilisant une proteine de liaison du facteur de  
 necrose tumorale (TNF) dans le traitement de maladies induites par le  
 TNF.  
 TIDE Kombinationstherapie mit einem tnf-bindendem Protein zur behandlung von  
 durch tnf verursachten Erkrankungen.  
 IN Bendele, Alison M., 6583 Magnolia Road, Nederland, CO 80466, US;  
 Edwards, Carl K. III, 1620 South Pitkin Avenue, Superior, CO 80301, US

PA Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US  
 PAN 2570213  
 AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietät,  
 Maximilianstrasse 58, 80538 Muenchen, DE  
 AGN 100721  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPA2 Application published without search report  
 PI EP 1352656 A2 20031015  
 EP 1352656 A3 20040204  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV MK RO SI  
 AI EP 2003-15211 A 19971208  
 RLI EP 1997-953156 19980611 EP 942740 Parent Application  
 PRAI US 1996-32587P P 19961206  
 US 1997-36355P P 19970123  
 US 1997-39315P P 19970207  
 US 1997-52023P P 19970709  
 IC.VER 7  
 ICM A61K038-17  
 ICS A61P019-02; A61P029-00  
 ICI A61K038-17, A61K031:519  
  
 AN 2003:16425 EPFULL  
 DUPD 20040204 DUPW 200406  
 TIEN Combination therapy using a TNF binding protein for treating  
 TNF-mediated diseases.  
 TIFR Therapie combinatoire utilisant une proteine de liaison du facteur de  
 necrose tumorale (TNF) dans le traitement de maladies induites par le  
 TNF.  
 TIDE Kombinationstherapie mit einem tnf-bindendem Protein zur behandlung von  
 durch tnf verursachten Erkrankungen.  
 IN Bendele, Alison M., 6583 Magnolia Road, Nederland, CO 80466, US;  
 Edwards, Carl K. III, 1620 South Pitkin Avenue, Superior, CO 80301, US  
 PA Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US  
 PAN 2570213  
 AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietät,  
 Maximilianstrasse 58, 80538 Muenchen, DE  
 AGN 100721  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPA3 Separate publication of search report  
 PI EP 1352656 A3 20040204  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV MK RO SI  
 AI EP 2003-15211 A 19971208  
 RLI EP 1997-953156 19980611 EP 942740 Parent Application  
 PRAI US 1996-32587P P 19961206  
 US 1997-36355P P 19970123  
 US 1997-39315P P 19970207  
 US 1997-52023P P 19970709  
 IC.VER 7  
 ICM A61K038-17  
 ICS A61P019-02; A61P029-00  
 ICI A61K038-17, A61K031:519  
  
 L4 ANSWER 4 OF 43 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN

AN 1997:89641 EPFULL  
 DUPD 20031112 DUPW 200346  
 TIEN ANTIGENIC MODULATION OF CELLS.  
 TIFR MODULATION ANTIGENIQUE DE CELLULES.  
 TIDE ANTIGENE MODULATION VON ZELLEN.  
 IN BYUN, Si-Myung, Hanul Apartments, 1102, 109-dong, Sinsong-dong,  
 Taejon-Kwangyoksi 305-345, KR;  
 EATON, John, Baylor College of Medicine, Texas Medical Center, 1 Baylor  
 Plaza, Houston, TX 77030-3498, US;  
 JEONG, Seong-Tae, Chugong Apts, 206, 104-dong, 59-1 Tanbang-dong, So-gu,  
 Taejon-Kwangyoski 302-223, KR;  
 SCOTT, Mark D., Albany Medical College, 47 New Scotland Avenue, Albany,  
 NY 12208, US  
 PA BIOMEDICAL FRONTIERS, INC., Hennepin Business Center, 1095 Tenth Avenue  
 S.E., Minneapolis, MN 55414, US  
 PAN 1001811  
 AG Evans, Claire, Edward Evans Barker Clifford's Inn Fetter Lane, London  
 EC4A 1BZ, GB  
 AGN 99621  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPA1 Application published with search report  
 PI EP 901521 A1 19990317  
 WO 9728254 19970807  
 DS CH DE ES FR GB IT LI NL  
 AI EP 1997-901754 A 19970203  
 WO 1997-IB139 A 19970203  
 PRAI KR 1996-2440 A 19960201  
 US 1996-671452 A 19960627  
 IC.VER 7  
 ICM C12N005-08  
 ICS A61K035-18; A61K035-12  
 AN 1997:89641 EPFULL ED 20051102 UP 20060823  
 DUPD 20060816 DUPW 200633  
 TIEN ANTIGENIC MODULATION OF CELLS.  
 TIFR MODULATION ANTIGENIQUE DE CELLULES.  
 TIDE ANTIGENE MODULATION VON ZELLEN.  
 IN BYUN, Si-Myung, Hanul Apartments, 1102, 109-dong, Sinsong-dong,  
 Taejon-Kwangyoksi 305-345, KR;  
 EATON, John, Baylor College of Medicine, Texas Medical Center, 1 Baylor  
 Plaza, Houston, TX 77030-3498, US;  
 JEONG, Seong-Tae, Chugong Apts, 206, 104-dong, 59-1 Tanbang-dong,  
 So-gu, Taejon-Kwangyoski 302-223, KR;  
 SCOTT, Mark D., Albany Medical College, 47 New Scotland Avenue, Albany,  
 NY 12208, US  
 PA BIOMEDICAL FRONTIERS, INC., Hennepin Business Center, 1095 Tenth Avenue  
 S.E., Minneapolis, MN 55414, US  
 PAN 1001811  
 AG Evans, Claire, Marks & Clerk Incorporating Edward Evans Barker 90 Long  
 Acre, London WC2E 9RA, GB  
 AGN 99621  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPB1 Granted patent  
 PI EP 901521 B1 20051102  
 WO 9728254 19970807  
 DS CH DE ES FR GB IT LI NL

AI	EP 1997-901754	A	19970203
	WO 1997-IB139	A	19970203
PRAI	KR 1996-2440	A	19960201
	US 1996-671452	A	19960627
REN	J BIOMATER SCI POLYM ED 4 (6). 1993. 579-589, XP000673687 HAN D K ET AL: "PREPARATION AND SURFACE PROPERTIES OF PEO -SULFONATE GRAFTED POLYURETHANES FOR ENHANCED BLOOD COMPATIBILITY."; ARTIF. CELLS, BLOOD SUBSTITUTES, IMMOBILIZATION BIOTECHNOL. (1996), 24(5), 503-511, 1996, XP000673685 JEONG, SEONG TAE ET AL: "Decreased agglutinability of methoxy-polyethylene glycol attached red blood cells: Significance as a blood substitute"		
REP	WO 8604145	A	
	WO 9205801	A	
	WO 9318649	A	
	WO 9526740	A	
IPCI	C12N0005-08 [I,A]; A61K0035-18 [I,A]; A61K0035-12 [I,A] C12N0005-08 [I,C*]; A61K0035-18 [I,C*]; A61K0035-12 [I,C*]		
L4	ANSWER 5 OF 43 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN		
AN	1997:78664 EPFULL DUPD 19981111 DUPW 199846		
TIEN	KERATINOCYTE GROWTH FACTORS AND USES THEREOF.		
TIFR	FACTEURS DE CROISSANCE DES KERATINOCYTES ET LEURS UTILISATIONS.		
IN	FARRELL, Catherine, L., 28051 Magic Mountain Lane, Canyon Country, CA 91351, US; LI, Yue-Sheng, 3565 Birdsong Avenue, Thousand Oaks, CA 91360, US		
PA	AMGEN INC., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789, US		
PAN	923233		
DT	Patent		
LAF	English		
LA	English		
LAP	English		
TL	English; French		
PIT	WOA2 International application published without search report		
PI	WO 9824813	A2	19980611
DS	AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE		
AI	EP 1997-953157	A	19971208
	WO 1997-US22735	A	19971208
PRAI	US 1996-32533P	P	19961206
	US 1997-62074P	P	19971015
IC.VER	6		
ICM	C07K014-00		
ICS	C07K014-605; A61K038-18		
AN	1997:78664 EPFULL DUPD 20020306 DUPW 200210		
TIEN	USE OF A KGF PROTEIN PRODUCT(S) AND A GLP-2 PROTEIN PRODUCT(S) FOR THE PREPARATION OF A MEDICAMENT.		
TIFR	UTILISATION DE PRODUIT(S) PROTEIQUE(S) KGF ET DE PRODUIT(S) PROTEIQUE(S) GLP-2 POUR LA PREPARATION D'UN MEDICAMENT.		
TIDE	VERWENDUNG EINES KGF-PROTEINPRODUKTES UND EINES GLP-2 PROTEINPRODUKTES FUEr DIE HERSTELLUNG EINES MEDIKAMENTES.		
IN	FARRELL, Catherine, L., 28051 Magic Mountain Lane, Canyon Country, CA 91351, US; LI, Yue-Sheng, 3565 Birdsong Avenue, Thousand Oaks, CA 91360, US		
PA	Amgen Inc.,, One Amgen Center Drive, Thousand Oaks, California 91320-1799, US		
PAN	923239		
AG	Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietet, Maximilianstrasse 58, 80538 Muenchen, DE		
AGN	100721		
DT	Patent		

LAF English  
 LA English  
 LAP English  
 PIT EPA2 Application published without search report  
 PI EP 1012186 A2 20000628  
 WO 9824813 19980611  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV MK RO SI  
 AI EP 1997-953157 A 19971208  
 WO 1997-US22735 A 19971208  
 PRAI US 1996-32533P P 19961206  
 US 1997-62074P P 19971015  
 IC.VER 7  
 ICM C07K014-50  
 ICS C07K014-605; A61K038-18; A61K038-26  
  
 AN 1997:78664 EPFULL  
 DUPD 20030709 DUPW 200328  
 TIEN USE OF A KGF PROTEIN PRODUCT(S) AND A GLP-2 PROTEIN PRODUCT(S) FOR THE  
 PREPARATION OF A MEDICAMENT.  
 TIFR UTILISATION DE PRODUIT(S) PROTEIQUE(S) KGF ET DE PRODUIT(S)  
 PROTEIQUE(S) GLP-2 POUR LA PREPARATION D'UN MEDICAMENT.  
 TIDE VERWENDUNG EINES KGF-PROTEINPRODUKTES UND EINES GLP-2 PROTEINPRODUKTES  
 FUEr DIE HERSTELLUNG EINES MEDIKAMENTES.  
 IN FARRELL, Catherine, L., 28051 Magic Mountain Lane, Canyon Country, CA  
 91351, US;  
 LI, Yue-Sheng, 3565 Birdsong Avenue, Thousand Oaks, CA 91360, US  
 PA Amgen Inc.,, One Amgen Center Drive, Thousand Oaks, California  
 91320-1799, US  
 PAN 923239  
 AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietet,  
 Maximilianstrasse 58, 80538 Muenchen, DE  
 AGN 100721  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPB1 Granted patent  
 PI EP 1012186 B1 20020717  
 WO 9824813 19980611  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV MK RO SI  
 AI EP 1997-953157 A 19971208  
 WO 1997-US22735 A 19971208  
 PRAI US 1996-32533P P 19961206  
 US 1997-62074P P 19971015  
 REN D J DRUCKER ET AL.: "Induction of intestinal epithelial proliferation by  
 glucagon-2 like peptide" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES  
 OF USA., vol. 93, no. 15, 23 July 1996, WASHINGTON US, pages 7911-7916,  
 XP000602070;  
 BIOLOGICAL ABSTRACTS, vol. 102, no. 7, 1996 Philadelphia, PA, US;  
 abstract no. 96747, M BRAUCHLE ET AL.: "Keratinocyte growth factor is  
 highly overexpressed on inflammatory bowel disease" XP002063839 &  
 AMERICAN JOURNAL OF PATHOLOGY, vol. 149, no. 2, August 1996, pages  
 521-529,  
 IC.VER 7  
 ICM C07K014-50  
 ICS C07K014-605; A61K038-18; A61K038-26  
  
 L4 ANSWER 6 OF 43 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN  
  
 AN 1997:78354 EPFULL  
 DUPD 19981111 DUPW 199846



TIEN COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING  
 TNF-MEDIATED DISEASES.  
 TIFR THERAPIE.COMBINATOIRE UTILISANT UNE PROTEINE DE LIAISON DU FACTEUR DE  
 NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DE MALADIES INDUITES PAR LE  
 TNF.  
 IN BENDELE, Alison, M., 6583 Magnolia Road, Nederland, CO 80466, US;  
 SENNELLO, Regina, M., 948 Deer Trail Road, Boulder, CO 80302, US;  
 EDWARDS, Carl, K., 1620 South Pitkin Avenue, Superior, CO 80301, US  
 PA AMGEN INC., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA  
 91320-1789, US  
 PAN 923233  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL English; French  
 PIT WOA2 International application published without search report  
 PI WO 9824463 A2 19980611  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 AI EP 1997-953156 A 19971208  
 WO 1997-US22733 A 19971208  
 PRAI US 1996-32587P P 19961206  
 US 1997-36355P P 19970123  
 US 1997-39315P P 19970207  
 US 1997-52023P P 19970709  
 IC.VER 6  
 ICM A61K038-00  
 ICS A61K031-00; C07K014-00; A61K038-17  
  
 AN 1997:78354 EPFULL  
 DUPD 20030827 DUPW 200335  
 TIEN COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING  
 TNF-MEDIATED DISEASES.  
 TIFR THERAPIE.COMBINATOIRE UTILISANT UNE PROTEINE DE LIAISON DU FACTEUR DE  
 NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DE MALADIES INDUITES PAR LE  
 TNF.  
 TIDE KOMBINATIONTHERAPIE MIT EINEM TNF-BINDENDEM PROTEIN ZUER BEHANDLUNG VON  
 DURCH TNF VERURSACHTEN ERKRANKUNGEN.  
 IN BENDELE, Alison, M., 6583 Magnolia Road, Nederland, CO 80466, US;  
 SENNELLO, Regina, M., 948 Deer Trail Road, Boulder, CO 80302, US;  
 EDWARDS, Carl, K., 1620 South Pitkin Avenue, Superior, CO 80301, US  
 PA Amgen Inc.,, One Amgen Center Drive, Thousand Oaks, California  
 91320-1799, US  
 PAN 923239  
 AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietat,  
 Maximilianstrasse 58, 80538 Muenchen, DE  
 AGN 100721  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPA2 Application published without search report  
 PI EP 942740 A2 19990922  
 WO 9824463 19980611  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV MK RO SI  
 AI EP 1997-953156 A 19971208  
 WO 1997-US22733 A 19971208  
 RLI EP 2003-15211 20030704  
 PRAI US 1996-32587P P 19961206  
 US 1997-36355P P 19970123  
 US 1997-39315P P 19970207  
 US 1997-52023P P 19970709

Divisional Application

IC.VER 7  
 ICM A61K038-17  
 ICS A61K031-4155; C07K014-715; A61P029-00; A61P019-02

AN 1997:78354 EPFULL  
 DUPD 20040818 DUPW 200434

TIEN COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING  
 TNF-MEDIATED DISEASES.

TIFR THERAPIE COMBINATOIRE UTILISANT UNE PROTEINE DE LIAISON DU FACTEUR DE  
 NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DE MALADIES INDUITES PAR LE  
 TNF.

TIDE KOMBINATIONTHERAPIE MIT EINEM TNF-BINDENDEN PROTEIN ZUER BEHANDLUNG VON  
 DURCH TNF VERURSACHTEN ERKRANKUNGEN.

IN BENDELE, Alison, M., 6583 Magnolia Road, Nederland, CO 80466, US;  
 SENNELLO, Regina, M., 948 Deer Trail Road, Boulder, CO 80302, US;  
 EDWARDS, Carl, K., 1620 South Pitkin Avenue, Superior, CO 80301, US

PA Amgen Inc., One Amgen Center Drive, Thousand Oaks, California  
 91320-1799, US

PAN 923239

AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietet,  
 Maximilianstrasse 58, 80538 Muenchen, DE

AGN 100721

DT Patent

LAF English

LA English

LAP English

TL German; English; French

PIT EPB1 Granted patent

PI EP 942740 B1 20030827  
 WO 9824463 19980611

DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV MK RO SI

AI EP 1997-953156 A 19971208  
 WO 1997-US22733 A 19971208

RLI EP 2003-15211 20030704 EP 1352656 Divisional Application

PRAI US 1996-32587P P 19961206  
 US 1997-36355P P 19970123  
 US 1997-39315P P 19970207  
 US 1997-52023P P 19970709

REN KAVANAUGH A F ET AL: "ANTI-TNF-ALPHA MONOCLONAL ANTIBODY (MAB)  
 TREATMENT OF RHEUMATOID ARTHRITIS (RA) PATIENTS WITH ACTIVE DISEASE ON  
 METHOTREXATE (MTX); RESULTS OF A DOUBLE-BLIND, PLACEBO CONTROLLED  
 MULTICENTER TRIAL" ARTHRITIS & RHEUMATISM, vol. 39, no. 9, September  
 1996, page S123 XP002048557;  
 BARRERA P ET AL: "Circulating soluble tumor necrosis factor  
 receptors, interleukin-2 receptors, tumor necrosis factor alpha, and  
 interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation  
 during methotrexate and azathioprine therapy [see comments]." ARTHRITIS  
 AND RHEUMATISM, (1993 AUG) 36 (8) 1070-9, XP002063595;  
 SEITZ M ET AL: "Methotrexate action in rheumatoid arthritis:  
 stimulation of cytokine inhibitor and inhibition of chemokine production  
 by peripheral blood mononuclear cells." BRITISH JOURNAL OF RHEUMATOLOGY,  
 (1995 JUL) 34 (7) 602-9, XP002063596;  
 SEITZ M ET AL: "Interleukin 1 (IL-1) receptor antagonist, soluble  
 tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of  
 remission in rheumatoid arthritis during treatment with methotrexate."  
 JOURNAL OF RHEUMATOLOGY, (1996 SEP) 23 (9) 1512-6, XP002063597;  
 BOLOGNA C ET AL: "ASSOCIATION DES TRAITEMENTS DE FOND DANS LA  
 POLYARTHRITE RHUMATOIDE" PRESSE MEDICALE, vol. 25, no. 19, 1 June 1996,  
 pages 876-878, XP002048553;  
 BORIGINI M J ET AL: "COMBINATION THERAPY" BAILLIERE S CLINICAL  
 RHEUMATOLOGY, vol. 9, no. 4, November 1995, pages 689-710, XP002048554

REP WO 9207585 A  
 WO 9406476 A

WO 9620729 A  
 WO 9805357 A  
 IC.VER 7  
 ICM A61K038-17  
 ICS A61K031-4155; C07K014-715; A61P029-00; A61P019-02  
  
 L4 ANSWER 7 OF 43 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN  
  
 AN 1997:68787 EPFULL  
 DUPD 19980902 DUPW 199836  
 TIEN USES OF KERATINOCYTE GROWTH FACTOR-2.  
 TIFR UTILISATIONS DU FACTEUR-2 DE CROISSANCE DE KERATINOCYTE.  
 IN LACEY, David, L., 614 Paseo Vista, Thousand Oaks, CA 91320, US;  
 ULICH, Thomas, R., 13068 Lexington Hills Drive, Camarillo, CA 93012, US;  
 DANILENKO, Dimitry, M., 13082 Rancho Vista Court, Camarillo, CA 93012,  
 US;  
 FARRELL, Catherine, L., 28051 Magic Mountain Lane, Canyon Country, CA  
 91351, US  
 PA AMGEN INC., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA  
 91320-1789, US  
 PAN 923233  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL English; French  
 PIT WOA1 International application published with search report  
 PI WO 9816243 A1 19980423  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 AI EP 1997-913676 A 19971015  
 WO 1997-US18667 A 19971015  
 PRAI US 1996-28495P P 19961015  
 US 1996-32253P P 19961206  
 US 1996-33457P P 19961210  
  
 IC.VER 6  
 ICM A61K038-18  
  
 AN 1997:68787 EPFULL  
 DUPD 20030820 DUPW 200334  
 TIEN USES OF KERATINOCYTE GROWTH FACTOR-2.  
 TIFR UTILISATIONS DU FACTEUR-2 DE CROISSANCE DE KERATINOCYTE.  
 TIDE VERWENDUNG VON KERATINOCYTEN-WACHSTUMSFAKTOR-2.  
 IN LACEY, David, L., 614 Paseo Vista, Thousand Oaks, CA 91320, US;  
 ULICH, Thomas, R., 13068 Lexington Hills Drive, Camarillo, CA 93012, US;  
 DANILENKO, Dimitry, M., 13082 Rancho Vista Court, Camarillo, CA 93012,  
 US;  
 FARRELL, Catherine, L., 29441 Mulholland Hwy., Agoura, California 91301,  
 US  
 PA Amgen Inc.,, One Amgen Center Drive, Thousand Oaks, California  
 91320-1799, US  
 PAN 923239  
 AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietat,  
 Maximilianstrasse 58, 80538 Muenchen, DE  
 AGN 100721  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPA1 Application published with search report  
 PI EP 941110 A1 19990915  
 WO 9816243 19980423  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV RO SI

AI	EP 1997-913676	A	19971015
	WO 1997-US18667	A	19971015
PRAI	US 1996-28495P	P	19961015
	US 1996-32253P	P	19961206
	US 1996-33457P	P	19961210

IC.VER 7  
ICM A61K038-18  
ICS A61P043-00

AN 1997:68787 EPFULL UP 20050209  
DUPD 20050209 DUPW 200506

TIEN USES OF KERATINOCYTE GROWTH FACTOR-2.  
TIFR UTILISATIONS DU FACTEUR-2 DE CROISSANCE DE KERATINOCYTE.  
TIDE VERWENDUNG VON KERATINOCYTEN-WACHSTUMSFAKTOR-2.  
IN LACEY, David, L., 614 Paseo Vista, Thousand Oaks, CA 91320, US;  
ULICH, Thomas, R., 13068 Lexington Hills Drive, Camarillo, CA 93012, US;  
DANILENKO, Dimitry, M., 13082 Rancho Vista Court, Camarillo, CA 93012,  
US;  
FARRELL, Catherine, L., 29441 Mulholland Hwy., Agoura, California 91301,  
US

PA Amgen Inc.,, One Amgen Center Drive, Thousand Oaks, California  
91320-1799, US

PAN 923239  
AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietat,  
Maximilianstrasse 58, 80538 Muenchen, DE

AGN 100721  
DT Patent  
LAF English  
LA English  
LAP English  
TL German; English; French  
PIT EPB1 Granted patent  
PI EP 941110 B1 20040218  
WO 9816243 19980423

DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
EXTENSION STATES: AL LT LV RO SI

AI	EP 1997-913676	A	19971015
	WO 1997-US18667	A	19971015

RLI	EP 2004-3545	20040217	EP 1452205 Divisional Application
PRAI	US 1996-28495P	P	19961015
	US 1996-32253P	P	19961206
	US 1996-33457P	P	19961210

REN RUSSELL D ET AL: "Growth and differentiation effects of keratinocyte  
growth factor ( KGF ) on small intestinal mucosa." DIGESTIVE DISEASE  
WEEK AND THE 97TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL  
ASSOCIATION, WASHINGTON, D.C., USA, MAY 11-14, 1997. GASTROENTEROLOGY  
112 (4 SUPPL.). 1997. A903, XP002056078;  
SLAYDEN O D ET AL: "Keratinocyte growth factor ( KGF ) stimulates  
epithelial cell proliferation in the primate oviduct and vagina."  
THIRTIETH ANNUAL MEETING OF THE SOCIETY FOR THE STUDY OF REPRODUCTION,  
PORTLAND, OREGON, USA, AUGUST 2-5, 1997. BIOLOGY OF REPRODUCTION 56  
(SUPPL. 1). 1997. 103, XP002056079;  
JIMENEZ P ET AL: "EFFECT OF TOPICAL KERATINOCYTE GROWTH FACTOR-2 ON  
WOUND HEALING IN A GLUCOCORTICOID-IMPAIRED MODEL" JOURNAL OF CUTANEOUS  
PATHOLOGY, vol. 24, no. 2, February 1997, page 105 XP002051178;  
JIMENEZ P A ET AL: "EFFECT OF KERATINOCYTE GROWTH FACTOR-2 ON CELL  
PROLIFERATION IN VIVO" FASEB JOURNAL, vol. 11, no. 3, 6 April 1997, page  
A523 XP002051177

REP	EP 619370	A
	WO 9625422	A
	WO 9713857	A

IC.VER 7  
ICM A61K038-18  
ICS A61P043-00

L4 ANSWER 8 OF 43 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN

AN 1997:68314 EPFULL  
DUPD 19980826 DUPW 199835  
TIEN KERATINOCYTE GROWTH FACTOR-2 PRODUCTS.  
TIFR PRODUITS A BASE DU FACTEUR DE CROISSANCE 2 DES KERATINOCYTES.  
IN NARHI, Linda, Owens, 2890 North Los Cedros Circle, Camarillo, CA 93012,  
US;  
OSSLUND, Timothy, D., 475 Vista Montana, Camarillo, CA 93012, US  
PA AMGEN INC., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA  
91320-1789, US  
PAN 923233  
DT Patent  
LAF English  
LA English  
LAP English  
TL English; French  
PIT WOA1 International application published with search report  
PI WO 9816642 A1 19980423  
DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
AI EP 1997-910119 A 19971015  
WO 1997-US18607 A 19971015  
PRAI US 1996-28493P P 19961015  
US 1996-32781P P 19961206  
US 1996-33046P P 19961211  
IC.VER 6  
ICM C12N015-12  
ICS C12N015-62; C12N015-70; C12N001-21; C07K014-50; A61K038-18

AN 1997:68314 EPFULL  
DUPD 20001220 DUPW 200051  
TIEN KERATINOCYTE GROWTH FACTOR-2 PRODUCTS.  
TIFR PRODUITS A BASE DU FACTEUR DE CROISSANCE 2 DES KERATINOCYTES.  
TIDE PRODUKTE DES KERATINOCYTEN-WACHSTUMSFAKTORS 2 (KGF-2).  
IN NARHI, Linda, Owens, 2890 North Los Cedros Circle, Camarillo, CA 93012,  
US;  
OSSLUND, Timothy, D., 475 Vista Montana, Camarillo, CA 93012, US  
PA Amgen Inc., (Amgen, Inc.), One Amgen Center Drive, Thousand Oaks, CA  
91320-1789, US  
PAN 923239  
AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietat,  
Maximilianstrasse 58, 80538 Muenchen, DE  
AGN 100721  
DT Patent  
LAF English  
LA English  
LAP English  
TL German; English; French  
PIT EPA1 Application published with search report  
PI EP 935652 A1 19990818  
WO 9816642 19980423  
DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
EXTENSION STATES: AL LT LV RO SI  
AI EP 1997-910119 A 19971015  
WO 1997-US18607 A 19971015  
PRAI US 1996-28493P P 19961015  
US 1996-32781P P 19961206  
US 1996-33046P P 19961211  
IC.VER 7  
ICM C12N015-12  
ICS C12N015-62; C12N015-70; C12N001-21; C07K014-50; A61K038-18

AN 1997:68314 EPFULL UP 20050323

DUPD 20050323 DUPW 200512  
 TIEN KERATINOCYTE GROWTH FACTOR-2 PRODUCTS.  
 TIFR PRODUITS A BASE DU FACTEUR DE CROISSANCE 2 DES KERATINOCYTES.  
 TIDE PRODUKTE DES KERATINOCYTEN-WACHSTUMSFAKTORS 2 (KGF-2).  
 IN NARHI, Linda, Owens, 2890 North Los Cedros Circle, Camarillo, CA 93012, US;  
 OSSLUND, Timothy, D., 475 Vista Montana, Camarillo, CA 93012, US  
 PA Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, US  
 PAN 923239  
 AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietat, Maximilianstrasse 58, 80538 Muenchen, DE  
 AGN 100721  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPB1 Granted patent  
 PI EP 935652 B1 20040331  
 WO 9816642 19980423  
 DS AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: AL LT LV RO SI  
 AI EP 1997-910119 A 19971015  
 WO 1997-US18607 A 19971015  
 RLI EP 2004-7578 20040329 EP 1473366 Divisional Application  
 PRAI US 1996-28493P P 19961015  
 US 1996-32781P P 19961206  
 US 1996-33046P P 19961211  
 REP WO 9501434 A  
 WO 9521258 A  
 WO 9611949 A  
 WO 9611951 A  
 WO 9625422 A  
 IC.VER 7  
 ICM C12N015-12  
 ICS C12N015-62; C12N015-70; C12N001-21; C07K014-50; A61K038-18  
 L4 ANSWER 9 OF 43 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN  
 AN 1995:4583 EPFULL  
 DUPD 19960103 DUPW 199601  
 TIEN Compositions and methods for stimulating megakaryocyte growth and differentiation.  
 TIFR Compositions et procede pour la stimulation de la croissance et la differentiation des megacaryocytes.  
 TIDE Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten.  
 IN Bartley, Timothy D., 2431 McCrea Road, Thousand Oaks, CA 91362, US;  
 Bogenberger, Jakob M., 2242 Barbara Drive, Camarillo, CA 93010, US;  
 Bosselman, Robert A., 3301 Baccarat Street, Thousand Oaks, CA 91362, US;  
 Hunt, Pamela, 2431 McCrea Road, Thousand Oaks, CA 91362, US;  
 Samal, Babru B., 1136 Broadview Drive, Moorpark, CA 93021, US;  
 Kinstler, Olaf B., P.O. Box 271, Newbury Park, CA 91320, US  
 PA AMGEN INC., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789, US  
 PAN 923233  
 AG Brown, John David, et al, FORRESTER & BOEHMERT Franz-Joseph-Strasse 38, 80801 Muenchen, DE  
 AGN 28811  
 DT Patent  
 LAF English  
 LA English  
 LAP English

TL German; English; French  
 PIT EPA1 Application published with search report  
 PI EP 690127 A1 19960103  
 DS AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: LT SI  
 AI EP 1995-104745 A 19950330  
 PRAI US 1994-221768 A 19940331  
 US 1994-252628 A 19940531  
 US 1994-321488 A 19941012  
 US 1994-347780 A 19941130  
 IC.VER 6  
 ICM C12N015-19  
 ICS C07K014-52; C07K017-08; A61K038-19; A61K047-48  
  
 AN 1995:4583 EPFULL  
 DUPD 19990728 DUPW 199930  
 TIEN Compositions and methods for stimulating megakaryocyte growth and differentiation.  
 TIFR Compositions et procede pour la stimulation de la croissance et la differentiation des megacaryocytes.  
 TIDE Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten.  
 IN Bartley, Timothy D., 2431 McCrea Road, Thousand Oaks, CA 91362, US;  
 Bogenberger, Jakob M., 2242 Barbara Drive, Camarillo, CA 93010, US;  
 Bosselman, Robert A., 3301 Baccarat Street, Thousand Oaks, CA 91362, US;  
 Hunt, Pamela, 2431 McCrea Road, Thousand Oaks, CA 91362, US;  
 Samal, Babru B., 1136 Broadview Drive, Moorpark, CA 93021, US;  
 Kinstler, Olaf B., P.O. Box 271, Newbury Park, CA 91320, US  
 PA AMGEN INC., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789, US  
 PAN 923233  
 AG Brown, John David, et al, FORRESTER & BOEHMERT Franz-Joseph-Strasse 38, 80801 Muenchen, DE  
 AGN 28811  
 DT Patent  
 LAF English  
 LA English  
 LAP English  
 TL German; English; French  
 PIT EPB1 Granted patent  
 PI EP 690127 B1 19980805  
 DS AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  
 EXTENSION STATES: LT SI  
 AI EP 1995-104745 A 19950330  
 PRAI US 1994-221768 A 19940331  
 US 1994-252628 A 19940531  
 US 1994-321488 A 19941012  
 US 1994-347780 A 19941130  
 REN EXPERIMENTAL HEMATOLOGY, vol.16, pages 201 - 205 MCDONALD  
 'THROMBOPOIETIN:ITS BIOLOGY,PURIFICATION,AND CHARACTERIZATION';  
 EXPERIMENTAL HEMATOLOGY, vol.17, no.8, 9 pages 865 - 871 MCDONALD ET AL  
 'A FOUR-STEP PROCEDURE FOR THE PURIFICATION OF THROMBOPOIETIN';  
 DATABASE CHEMICAL ABSTRACTS FILE SERVER STN KARLSRUHE ABSTRACT  
 119:210722 MYOSHI ET AL 'PEPITDES FOR PHARMACEUTICALS' & JP-A-5 097 694 (DENKI KAGAKU KOGYO KK);  
 CELL, vol.77, 1 July 1994 pages 1117 - 1124 BARTLEY ET AL  
 'IDENTIFICATION AND CLONING OF A MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR THAT IS A LIGAND FOR THE CYTOKINE RECEPTOR MPL';  
 NATURE, vol.369, 16 June 1994 pages 533 - 538 DE SAUVAGE ET AL  
 'STIMULATION OF MEGAKARYOCYTOPOIESIS AND THROMBOPOIESIS BY THE C-MPL LIGAND';  
 THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol.270, no.2, 13 January 1995 pages 511 - 514 CHANG ET AL 'CLONING AND CHARACTERIZATION OF THE HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (MGDF) GENE';

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol.91, 4 pages  
13023 - 13027 FOSTER ET AL 'HUMAN THROMBOPOIETIN: GENE STRUCTURE, CDNA  
SEQUENCE, EXPRESSION, AND CHROMOSOMAL LOCALIZATION'

REP EP 668352 A  
WO 8906546 A  
WO 9004606 A  
WO 9300109 A  
WO 9518858 A  
US 4002531 A  
US 4640835 A

IC.VER 6  
ICM C12N015-19  
ICS C07K014-52; C07K017-08; A61K038-19; A61K047-48

L4 ANSWER 10 OF 43 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN

AN 1995:4550 EPFULL UP 20060419  
DUPD 20060419 DUPW 200616

TIEN Compositions and methods for stimulating megakaryocyte growth and differentiation.

TIFR Compositions et procedes pour la stimulation de la croissance et la differenciation des megacaryocytes.

TIDE Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten.

IN Bartley, Timothy D., 2431 McCrea Road, Thousand Oaks, CA 91362, US;  
Bogenberger, Jakob M., 2242 Barbara Drive, Camarillo, CA 93010, US;  
Bosselman, Robert A., 3301 Baccarat Street, Thousand Oaks, CA 91362, US;  
Hunt, Pamela, 2431 McCrea Road, Thousand Oaks, CA 91362, US;  
Samal, Babru B., 1136 Broadview Drive, Moorpark, CA 93021, US;  
Kinstler, Olaf B., P.O.Box 271, Newbury Park, CA 91320, US

PA Amgen Inc., One Amgen Center Drive, Thousand Oaks, California  
91320-1799, US

PAN 923239

AG Brown, John D., et al, FORRESTER & BOEHMERT Pettenkoferstrasse 20-22,  
80336 Muenchen, DE

AGN 28811

DT Patent

LAF English

LA English

LAP English

TL German; English; French

PIT EPA1 Application published with search report

PI EP 675201 A1 19951004

DS AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  
EXTENSION STATES: LT SI

AI EP 1995-104711 A 19950330

PRAI US 1994-221768 A 19940331  
US 1994-252628 A 19940531  
US 1994-321488 A 19941012  
US 1994-347780 A 19941130

IPCI C12N0015-19 [I,A]; C07K0014-52 [I,A]; C12N0005-10 [I,A]; C07K0016-24  
[I,A]; A61K0038-19 [I,A]; C07K0017-08 [I,A]; A61K0047-48 [I,A]  
C12N0015-19 [I,C\*]; C07K0014-435 [I,C\*]; C12N0005-10 [I,C\*]; C07K0016-18  
[I,C\*]; A61K0038-19 [I,C\*]; C07K0017-00 [I,C\*]; A61K0047-48 [I,C\*]

L4 ANSWER 11 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN

AN 2006095029 PCTFULL ED 20060918 EW 200637

TIEN DI-POLYMER PROTEIN CONJUGATES AND PROCESSES FOR THEIR PREPARATION

TIFR CONJUGUES DI-POLYMER-PROTEINE ET PROCESSES DE PREPARATION DE CEUX-CI

IN BLASEY, Horst, Winkelstrasse 9, CH-4665 Oftringen, CH;  
LANG, Dietmar, Im Langen Loh 186, CH-4054 Basel, CH;  
BAVAND, Michael, Hintere Bahnhofstrasse 7, CH-5000 Aarau, CH

PA SIEGFRIED Ltd., Untere Bruehlstrasse 4, CH-4800 Zofingen, CH

AG HUENGES, Martin, Maiwald Patentanwalts GmbH, Elisenhof, Elisenstrasse 3,



80335 Muenchen, DE

LAF English  
 LA English  
 DT Patent  
 PI WO 2006095029 A2 20060914  
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID  
 IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY  
 MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO  
 RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ  
 VC VN YU ZA ZM ZW  
 RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW  
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM  
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT  
 LU LV MC NL PL PT RO SE SI SK TR  
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2006-EP60671 A 20060313  
 PRAI EP 2005-PCTEP05002632 20050311  
 IPCI C07K0014-535 [I,A]; A61K0047-48 [I,A]  
 C07K0014-435 [I,C\*]; A61K0047-48 [I,C\*]

L4 ANSWER 12 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
 AN 2006094530 PCTFULL ED 20060918 EW 200637  
 TIEN DI-POLYMER PROTEIN CONJUGATES AND PROCESSES FOR THEIR PREPARATION  
 TIFR CONJUGUES DE PROTEINES ET DE DIPOLYMERES ET LEURS PROCEDES DE  
 PREPARATION  
 IN LANG, Dietmar, Im Langen Loh 186, CH-4054 Basel, CH;  
 BLASEY, Horst, Winkelstrasse 9, CH-4665 Oftringen, CH;  
 BAVAND, Michael, Hintere Bahnhofstrasse 7, CH-5000 Aarau, CH  
 PA SIEGFRIED LTD., Untere Bruehlstrasse 4, CH-4800 Zofingen, CH  
 AG HUENGES, Martin, Maiwald Patentanwalts Gmbh, Elisenhof, Elisenstrasse 3,  
 80335 Muenchen, DE

LAF English  
 LA English  
 DT Patent  
 PI WO 2006094530 A1 20060914  
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID  
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG  
 MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE  
 SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA  
 ZM ZW  
 RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW  
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM  
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT  
 LU MC NL PL PT RO SE SI SK TR  
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2005-EP2632 A 20050311  
 IPCI C07K0014-535 [I,A]; A61K0047-48 [I,A]  
 C07K0014-435 [I,C\*]; A61K0047-48 [I,C\*]

L4 ANSWER 13 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
 AN 2004013205 PCTFULL ED 20040219 EW 200407  
 TIEN POLYETHYLENE GLYCOL ALDEHYDE DERIVATIVES  
 TIFR DERIVES ALDEHYDES DE POLYETHYLENE GLYCOL  
 IN WON, Chee-Youb, 91 Belmont Drive, Livingston, NJ 07039, US  
 PA F.HOFFMANN-LA ROCHE AG, 124 Grenzacherstrasse, CH-4070 Basle, CH [CH,  
 CH]  
 AG SCHAGER, Frank, 124 Grenzacherstrasse, CH-4070 Basle, CH

LAF English  
 LA English  
 DT Patent  
 PI WO 2004013205 A1 20040212  
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

		CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
		IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
		MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN
		TR TT TZ UA UG UZ VN YU ZA ZM ZW
RW (ARIPO):		GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO):		AM AZ BY KG KZ MD RU TJ TM
RW (EPO):		AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC
		NL PT RO SE SI SK TR
RW (OAPI):		BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI	WO 2003-EP7734	A 20030716
PRAI	US 2002-60/398,196	20020724
ICM	C08G065-329	
ICS	C07C047-198	
L4	ANSWER 14 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN	
AN	2004013165 PCTFULL ED 20040219 EW 200407	
TIEN	PEGYLATED T1249 POLYPEPTIDE	
TIFR	POLYPEPTIDE T1249 PEGYLE	
IN	BAILON, Pascal, Sebastian, 21 Woodbine Road, Florham Park, NJ 07932, US;	
	WON, Chee-Youb, 91 Belmont Drive, Livingston, NJ 07039, US	
PA	F. HOFFMANN-LA ROCHE AG, Grenzacherstrasse 124, CH-4070 Basel, CH [CH,	
	CH]	
AG	SCHAGER, Frank, Grenzacherstrasse 124, CH-4070 Basel, CH	
LAF	English	
LA	English	
DT	Patent	
PI	WO 2004013165	A1 20040212
DS	W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
		CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
		IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
		MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL SY TJ TM
		TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
RW (ARIPO):		GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO):		AM AZ BY KG KZ MD RU TJ TM
RW (EPO):		AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC
		NL PT RO SE SI SK TR
RW (OAPI):		BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI	WO 2003-EP7711	A 20030716
PRAI	US 2002-60/398,190	20020724
	US 2003-60/439,213	20030110
ICM	C07K014-16	
ICS	A61K038-16; A61P031-18	
L4	ANSWER 15 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN	
AN	2004013164 PCTFULL ED 20040219 EW 200407	
TIEN	PEGYLATED T20 POLYPEPTIDE	
TIFR	POLYPEPTIDE T20 PEGYLE	
IN	BAILON, Pascal, Sebastian, 21 Woodbine Road, Florham Park, NJ 07932, US;	
	WON, Chee-Youb, 91 Belmont Drive, Livingston, NJ 07039, US	
PA	F. HOFFMANN-LA ROCHE AG, Grenzacherstrasse 124, CH-4070 Basel, CH [CH,	
	CH]	
AG	SCHAGER, Frank, Grenzacherstrasse 124, CH-4070 Basel, CH	
LAF	English	
LA	English	
DT	Patent	
PI	WO 2004013164	A1 20040212
DS	W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
		CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
		IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
		MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL SY TJ TM
		TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
RW (ARIPO):		GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO):		AM AZ BY KG KZ MD RU TJ TM
RW (EPO):		AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC

NL PT RO SE SI SK TR  
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
 AI WO 2003-EP7710 A 20030716  
 PRAI US 2002-60/398,195 20020724  
 ICM C07K014-16  
 ICS A61K038-16; A61P031-18  
  
 L4 ANSWER 16 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
 AN 2000032772 PCTFULL ED 20020515  
 TIEN ERYTHROPOIETIC COMPOUNDS  
 TIFR COMPOSES ERYTHROPOIETIQUES  
 IN BEALS, John, Michael;  
 GLAESNER, Wolfgang;  
 MICANOVIC, Radmilla;  
 MILLICAN, Rohn, Lee, Jr.;  
 WITCHER, Derrick, Ryan  
 PA ELI LILLY AND COMPANY;  
 BEALS, John, Michael;  
 GLAESNER, Wolfgang;  
 MICANOVIC, Radmilla;  
 MILLICAN, Rohn, Lee, Jr.;  
 WITCHER, Derrick, Ryan  
 LA English  
 DT Patent  
 PI WO 2000032772 A2 20000608  
 DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK  
 DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP  
 KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL  
 PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN  
 YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ  
 MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC  
 NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG  
  
 AI WO 1999-US27801 A 19991123  
 PRAI US 1998-60/110,289 19981130  
 ICM C12N015-12  
 ICS C12N001-21; C07K014-505; A61K047-48; A61K038-18; A01K067-027; A61P007-06  
  
 L4 ANSWER 17 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
 AN 2000024697 PCTFULL ED 20020515  
 TIEN METHOD FOR PREPARATION OF POLYETHYLENE GLYCOL  
 ALDEHYDE DERIVATIVES  
 TIFR PROCEDE DE PREPARATION DE DERIVES ALDEHYDES DES POLYETHYLENEGLYCOLS  
 IN BAUDYS, Miroslav;  
 LIU, Feng;  
 KIM, Sung, Wan  
 PA UNIVERSITY OF UTAH RESEARCH FOUNDATION;  
 BAUDYS, Miroslav;  
 LIU, Feng;  
 KIM, Sung, Wan  
 LA English  
 DT Patent  
 PI WO 2000024697 A1 20000504  
 DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK  
 DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP  
 KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL  
 PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN  
 YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ  
 MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC  
 NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG  
  
 AI WO 1999-US25174 A 19991026  
 PRAI US 1998-60/105,630 19981026  
 ICM C07C043-10  
 ICS C07C047-12; C07C

L4 ANSWER 18 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
 AN 1999000145 PCTFULL ED 20020515  
 TIEN ANTIGENIC MODULATION OF VIRAL PARTICULES  
 TIFR MODULATION ANTIGENIQUE DE PARTICULES VIRALES  
 IN SCOTT, Mark, D.;  
 EATON, John, W.  
 PA ALBANY MEDICAL COLLEGE;  
 SCOTT, Mark, D.;  
 EATON, John, W.  
 LA English  
 DT Patent  
 PI WO 9900145 A1 19990107  
 DS W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
 FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR  
 LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG  
 SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW  
 SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK  
 ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA  
 GN ML MR NE SN TD TG  
 AI WO 1998-US13198 A 19980625  
 PRAI US 1997-08/883,447 19970626  
 ICM A61K047-48  
 ICS C12N015-88; C12N015-86

L4 ANSWER 19 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
 AN 1998024813 PCTFULL ED 20020514  
 TIEN KERATINOCYTE GROWTH FACTORS AND THEIR USE IN COMBINATION WITH  
 GLUCAGON-LIKE PEPTIDE DERIVATIVES  
 TIFR FACTEURS DE CROISSANCE DES KERATINOCYTES ET LEURS UTILISATIONS  
 IN FARRELL, Catherine, L.;  
 LI, Yue-Sheng  
 PA AMGEN INC.;  
 FARRELL, Catherine, L.;  
 LI, Yue-Sheng  
 LA English  
 DT Patent  
 PI WO 9824813 A2 19980611  
 DS W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
 FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT  
 LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK  
 SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG  
 ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB  
 GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE  
 SN TD TG  
 AI WO 1997-US22735 A 19971208  
 PRAI US 1996-60/032,533 19961206  
 US 1997-60/062,074 19971015  
 ICM C07K014-50  
 ICS C07K014:605; A61K038:18; A61K038:26

L4 ANSWER 20 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
 AN 1998024477 PCTFULL ED 20020514  
 TIEN COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED  
 DISEASES  
 TIFR THERAPIE COMBINEE UTILISANT UN INHIBITEUR DE L'IL-1 POUR TRAITER LES  
 MALADIES INDUITES PAR L'IL-1  
 IN BENDELE, Alison, M.;  
 SENNELLO, Regina, M.  
 PA AMGEN INC.;  
 BENDELE, Alison, M.;  
 SENNELLO, Regina, M.  
 LA English  
 DT Patent  
 PI WO 9824477 A1 19980611

DS W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
 FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT  
 LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK  
 SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG  
 ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB  
 GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE  
 SN TD TG

AI WO 1997-US22720 A 19971208  
 PRAI US 1996-60/032,790 19961206  
 US 1997-60/036,353 19970123  
 US 1997-60/039,311 19970207  
 US 1997-60/052,025 19970709

ICM A61K045-06  
 ICS A61K038:20; A61K038:20; A61K031:505

L4 ANSWER 21 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
 AN 1998001555 PCTFULL ED 20020514  
 TIEN TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS  
 TIFR RECEPTEURS DE TYPE I ET DE TYPE II DE FACTEUR DE NECROSE TUMORALE  
 TRONQUES ET SOLUBLES

IN FISHER, Eric, F.;  
 EDWARDS, Carl, K.;  
 KIEFT, Gary, L.

PA AMGEN INC.;  
 FISHER, Eric, F.;  
 EDWARDS, Carl, K.;  
 KIEFT, Gary, L.

LA English  
 DT Patent

PI WO 9801555 A2 19980115

DS W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
 FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU  
 LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL  
 TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG ZW AM  
 AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE  
 IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD  
 TG

AI WO 1997-US12244 A 19970709  
 PRAI US 1996-60/021,443 19960709  
 US 1996-60/032,534 19961206  
 US 1997-60/037,737 19970123  
 US 1997-60/039,314 19970207  
 US 1997-60/039,792 19970304

ICM C12N015-12  
 ICS C07K014:715; C07K001:107; A61K038:17; A61K047:48; A61K049:00;  
 C12N001:21; C12N005:10; G01N033:52; C12N001:21; C12R001:19

L4 ANSWER 22 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
 AN 1997028254 PCTFULL ED 20020514  
 TIEN ANTIGENIC MODULATION OF CELLS  
 TIFR MODULATION ANTIGENIQUE DE CELLULES

IN BYUN, Si-Myung;  
 EATON, John;  
 JEONG, Seong-Tae;  
 SCOTT, Mark, D.

PA BIOMEDICAL FRONTIERS, INC.;  
 SEABORN, George, Stephen;  
 BYUN, Si-Myung;  
 EATON, John;  
 JEONG, Seong-Tae;  
 SCOTT, Mark, D.

LA English  
 DT Patent

PI WO 9728254 A1 19970807

DS W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV  
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM  
TR TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD  
RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT  
SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AI WO 1997-IB139 A 19970203  
PRAI KR 1996-1996/2440 19960201  
US 1996-8/671,452 19960627  
ICM C12N005-08  
ICS A61K035:18; A61K035:12

L4 ANSWER 23 OF 43 PCTFULL COPYRIGHT 2006 Univentio on STN  
AN 1995026746 PCTFULL ED 20020514  
TIEN COMPOSITIONS AND METHODS FOR STIMULATING MEGAKARYOCYTE GROWTH AND  
DIFFERENTIATION  
TIFR COMPOSITIONS ET METHODES DE STIMULATION DE LA CROISSANCE ET DE LA  
DIFFERENTIATION DES MEGACARYOCYTES  
IN BARTLEY, Timothy, D.;  
BOGENBERGER, Jakob, M.;  
BOSELNMAN, Robert, A.;  
HUNT, Pamela;  
KINSTLER, Olaf, B.;  
SAMAL, Babru, B.

PA AMGEN INC.;  
BARTLEY, Timothy, D.;  
BOGENBERGER, Jakob, M.;  
BOSELNMAN, Robert, A.;  
HUNT, Pamela;  
KINSTLER, Olaf, B.;  
SAMAL, Babru, B.

LA English  
DT Patent

PI WO 9526746 A1 19951012  
DS W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU  
JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ  
PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN KE MW  
SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AI WO 1995-US3776 A 19950330  
PRAI US 1994-8/221,768 19940331  
US 1994-8/252,628 19940531  
US 1994-8/321,488 19941012  
US 1994-8/347,780 19941130  
ICM A61K038-16

ICS A61K038:18; C07H021:04; C07K001:12; C07K014:00; C07K014:435;  
C07K014:475; C12N015:00; C12N015:09; C12N015:12

L4 ANSWER 24 OF 43 USPATFULL on STN  
AN 2005:287430 USPATFULL  
TI Truncated soluble tumor necrosis factor type-I and type-II receptors  
IN Fisher, Eric F., New Braunfels, TX, UNITED STATES  
Edwards, Carl K. III, Superior, CO, UNITED STATES  
Kieft, Gary L., Boulder, CO, UNITED STATES  
PI US 2005250696 A1 20051110  
AI US 2005-126126 A1 20050510 (11)  
RLI Division of Ser. No. US 2001-882735, filed on 15 Jun 2001, PENDING  
Continuation of Ser. No. US 1999-214613, filed on 8 Jan 1999, ABANDONED  
A 371 of International Ser. No. WO 1997-US12244, filed on 9 Jul 1997  
PRAI US 1997-39792P 19970304 (60)  
US 1997-39314P 19970207 (60)  
US 1997-37737P 19970123 (60)  
US 1996-32534P 19961206 (60)  
US 1996-21443P 19960709 (60)

DT Utility  
 FS APPLICATION  
 LN.CNT 4528  
 INCL INCLM: 514/012.000  
 INCLS: 530/350.000  
 NCL NCLM: 514/012.000  
 NCLS: 530/350.000  
 IC [7]  
 ICM A61K038-17  
 ICS C07K014-715  
 IPCI A61K0038-17 [ICM,7]; C07K0014-715 [ICS,7]; C07K0014-435 [ICS,7,C\*]  
 IPCR A61K0038-17 [I,A]; A61K0038-17 [I,C\*]; C07K0014-435 [I,C\*]; C07K0014-715 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 43 USPATFULL on STN  
 AN 2005:10483 USPATFULL  
 TI Conjugates comprising human IL-18 and substitution mutants thereof  
 IN Bam, Narendra, King of Prussia, PA, UNITED STATES  
 Bongers, Jacob, King of Prussia, PA, UNITED STATES  
 Kirkpatrick, Robert B., King of Prussia, PA, UNITED STATES  
 Janson, Cheryl A., Hinsdale, IL, UNITED STATES  
 Jonak, Zdenka, King of Prussia, PA, UNITED STATES  
 Qiu, Xianyang, Mystic, CT, UNITED STATES  
 Yeh, Ping, King of Prussia, PA, UNITED STATES  
 Johanson, Kyung, King of Prussia, PA, UNITED STATES  
 PI US 2005008615 A1 20050113  
 AI US 2004-823964 A1 20040414 (10)  
 PRAI US 2003-462947P 20030415 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1910  
 INCL INCLM: 424/085.200  
 INCLS: 530/351.000  
 NCL NCLM: 424/085.200  
 NCLS: 530/351.000  
 IC [7]  
 ICM C07K014-54  
 ICS A61K038-20  
 IPCI C07K0014-54 [ICM,7]; C07K0014-435 [ICM,7,C\*]; A61K0038-20 [ICS,7]  
 IPCR A61K0038-20 [I,A]; A61K0038-20 [I,C\*]; C07K0014-435 [I,C\*]; C07K0014-54 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 43 USPATFULL on STN  
 AN 2004:221771 USPATFULL  
 TI Pegylated T1249 polypeptide  
 IN Bailon, Pascal Sebastian, Florham Park, NJ, UNITED STATES  
 Won, Chee-Youb, Livingston, NJ, UNITED STATES  
 PI US 2004171542 A1 20040902  
 US 7084261 B2 20060801  
 AI US 2003-625103 A1 20030722 (10)  
 PRAI US 2003-439213P 20030110 (60)  
 US 2002-398190P 20020724 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1472  
 INCL INCLM: 514/012.000  
 INCLS: 530/409.000  
 NCL NCLM: 530/402.000; 514/012.000  
 NCLS: 530/324.000; 530/409.000  
 IC [7]  
 ICM A61K038-17

ICS C07K014-705  
IPCI A61K0038-17 [ICM,7]; C07K0014-705 [ICS,7]; C07K0014-435  
[ICS,7,C\*]  
IPCI-2 A61K0038-12 [I,A]; C08H0001-00 [I,A]  
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; A61K0047-48 [I,A];  
A61K0047-48 [I,C\*]; C07K0014-005 [I,C\*]; C07K0014-155 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 43 USPATFULL on STN

AN 2004:135608 USPATFULL

TI Keratinocyte growth factor-2 products

IN Narhi, Linda Owers, Camarillo, CA, United States

Osslund, Timothy David, Camarillo, CA, United States

PA Amgen, Inc., Thousand Oaks, CA, United States (U.S. corporation)

PI US 6743422 B1 20040601

WO 9816642 19980423

AI US 1999-284100 19990407 (9)

WO 1997-US18607 19971015

PRAI US 1996-33046P 19961210 (60)

US 1996-32781P 19961206 (60)

US 1996-28493P 19961015 (60)

DT Utility

FS GRANTED

LN.CNT 3100

INCL INCLM: 424/085.100

INCLS: 514/002.000; 514/008.000; 514/012.000; 435/320.100; 435/252.300;  
435/254.110; 435/325.000; 435/069.100; 435/069.400; 530/351.000;  
530/350.000; 536/023.500; 536/023.100

NCL NCLM: 424/085.100

NCLS: 435/069.100; 435/069.400; 435/252.300; 435/254.110; 435/320.100;  
435/325.000; 514/002.000; 514/008.000; 514/012.000; 530/350.000;  
530/351.000; 536/023.100; 536/023.500

IC [7]

ICM C07K014-475

ICS C12N001-21; C12N005-16; C12N015-19; C12N015-63

IPCI C07K0014-475 [ICM,7]; C07K0014-435 [ICM,7,C\*]; C12N0001-21  
[ICS,7]; C12N0005-16 [ICS,7]; C12N0015-19 [ICS,7]; C12N0015-63  
[ICS,7]

IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; C07K0014-435 [I,C\*];  
C07K0014-50 [I,A]

EXF 530/399; 530/350; 530/351; 435/69.4; 435/71.1; 435/71.2; 435/325;  
435/352.3; 435/254.11; 435/320.1; 435/69.1; 536/23.5; 536/23.51; 574/2;  
574/5; 574/12; 424/85.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 43 USPATFULL on STN

AN 2004:64499 USPATFULL

TI Pegylated T20 polypeptide

IN Bailon, Pascal Sebastian, Florham Park, NJ, UNITED STATES

Won, Chee-Youb, Livingston, NJ, UNITED STATES

PI US 2004049018 A1 20040311

US 7049415 B2 20060523

AI US 2003-623873 A1 20030721 (10)

PRAI US 2002-398195P 20020724 (60)

DT Utility

FS APPLICATION

LN.CNT 947

INCL INCLM: 530/402.000

INCLS: 530/409.000; 525/054.100

NCL NCLM: 530/402.000

NCLS: 530/324.000; 525/054.100; 530/409.000

IC [7]

ICM C07K014-47

IPCI C07K0014-47 [ICM,7]; C07K0014-435 [ICM,7,C\*]



IPCI-2 A61K0038-12 [I,A]; C08H0001-00 [I,A]  
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; C07K0014-005 [I,C\*];  
C07K0014-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 43 USPATFULL on STN  
AN 2004:64280 USPATFULL  
TI Combination therapy using a TNF binding protein for treating  
TNF-mediated diseases  
IN Bendele, Alison M., Nederland, CO, UNITED STATES  
Sennello, Regina M., Boulder, CO, UNITED STATES  
Edwards, Carl K., III, Thousand Oaks, CA, UNITED STATES  
PA Amgen Inc. (U.S. corporation)  
PI US 2004048799 A1 20040311  
AI US 2003-622383 A1 20030716 (10)  
RLI Continuation of Ser. No. US 2001-907263, filed on 17 Jul 2001, PENDING  
Division of Ser. No. US 1999-326394, filed on 4 Jun 1999, GRANTED, Pat.  
No. US 6306820 Continuation of Ser. No. WO 1997-US22733, filed on 8 Dec  
1997, PENDING  
PRAI US 1996-32587P 19961206 (60)  
US 1997-36355P 19970123 (60)  
US 1997-39315P 19970207 (60)  
US 1997-52023P 19970709 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2591  
INCL INCLM: 514/012.000  
INCLS: 514/251.000  
NCL NCLM: 514/012.000  
NCLS: 514/251.000  
IC [7]  
ICM A61K038-17  
ICS A61K031-525  
IPCI A61K0038-17 [ICM,7]; A61K0031-525 [ICS,7]; A61K0031-519  
[ICS,7,C\*]  
IPCR A61K0038-17 [I,A]; A61K0038-17 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 43 USPATFULL on STN  
AN 2004:63345 USPATFULL  
TI Combination therapy using a TNF binding protein for treating  
TNF-mediated diseases  
IN Bendele, Alison M., Nederland, CO, UNITED STATES  
Sennello, Regina M., Boulder, CO, UNITED STATES  
Edwards, Carl K., III, Thousand Oaks, CA, UNITED STATES  
PA Amgen Inc. (U.S. corporation)  
PI US 2004047863 A1 20040311  
AI US 2003-621783 A1 20030716 (10)  
RLI Continuation of Ser. No. US 2001-907263, filed on 17 Jul 2001, PENDING  
Division of Ser. No. US 1999-326394, filed on 4 Jun 1999, GRANTED, Pat.  
No. US 6306820 Continuation of Ser. No. WO 1997-US22733, filed on 8 Dec  
1997, PENDING  
PRAI US 1996-32587P 19961206 (60)  
US 1997-36355P 19970123 (60)  
US 1997-39315P 19970207 (60)  
US 1997-52023P 19970709 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2590  
INCL INCLM: 424/145.100  
INCLS: 514/251.000; 514/012.000  
NCL NCLM: 424/145.100  
NCLS: 514/012.000; 514/251.000  
IC [7]

ICM A61K039-395  
ICS A61K031-525; A61K038-17  
IPCI A61K0039-395 [ICM,7]; A61K0031-525 [ICS,7]; A61K0031-519  
[ICS,7,C\*]; A61K0038-17 [ICS,7]  
IPCR A61K0038-17 [I,A]; A61K0038-17 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 43 USPATFULL on STN  
AN 2004:57917 USPATFULL  
TI Uses of keratinocyte growth factor-2  
IN Narhi, Linda Owens, Camarillo, CA, UNITED STATES  
Osslund, Timothy David, Camarillo, CA, UNITED STATES  
PI US 2004043924 A1 20040304  
AI US 2003-665526 A1 20030919 (10)  
RLI Continuation of Ser. No. US 1999-284100, filed on 7 Apr 1999, PENDING A  
371 of International Ser. No. WO 1997-US18607, filed on 15 Oct 1997,  
PENDING  
PRAI US 1996-33046P 19961210 (60)  
US 1996-32781P 19961206 (60)  
US 1996-28493P 19961015 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2891  
INCL INCLM: 514/008.000  
INCLS: 514/012.000; 530/399.000; 435/069.400; 435/320.100; 435/325.000  
NCL NCLM: 514/008.000  
NCLS: 435/069.400; 435/320.100; 435/325.000; 514/012.000; 530/399.000  
IC [7]  
ICM A61K038-18  
ICS C07K014-475  
IPCI A61K0038-18 [ICM,7]; C07K0014-475 [ICS,7]; C07K0014-435  
[ICS,7,C\*]  
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; C07K0014-435 [I,C\*];  
C07K0014-50 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 43 USPATFULL on STN  
AN 2004:25315 USPATFULL  
TI Polyethylene glycol aldehydes  
IN Won, Chee-Youb, Livingston, NJ, UNITED STATES  
PI US 2004019157 A1 20040129  
AI US 2003-623978 A1 20030721 (10)  
PRAI US 2002-398196P 20020724 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 974  
INCL INCLM: 525/403.000  
INCLS: 528/405.000  
NCL NCLM: 525/403.000  
NCLS: 528/405.000  
IC [7]  
ICM C08G065-00  
IPCI C08G0065-00 [ICM,7]  
IPCR C08G0065-00 [I,C\*]; C08G0065-324 [I,A]; C08G0065-329 [I,A];  
C08G0065-331 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 33 OF 43 USPATFULL on STN  
AN 2003:78519 USPATFULL  
TI Truncated soluble tumor necrosis factor type-I and type-II receptors  
IN Fisher, Eric F., New Braunfels, TX, UNITED STATES  
Edwards, Carl K., III, Superior, CO, UNITED STATES  
Kieft, Gary L., Boulder, CO, UNITED STATES  
PA Amgen Inc. (U.S. corporation)

PI US 2003054439 A1 20030320  
 US 6989147 B2 20060124  
 AI US 2001-882735 A1 20010615 (9)  
 RLI Continuation of Ser. No. US 1999-214613, filed on 8 Jan 1999, ABANDONED  
 A 371 of International Ser. No. WO 1997-US12244, filed on 9 Jul 1997,  
 UNKNOWN  
 PRAI US 1997-39792P 19970304 (60)  
 US 1997-39314P 19970207 (60)  
 US 1997-37737P 19970123 (60)  
 US 1996-32534P 19961206 (60)  
 US 1996-21443P 19960709 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4745  
 INCL INCLM: 435/069.100  
 INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
 NCL NCLM: 424/185.100; 435/069.100  
 NCLS: 424/134.100; 424/178.100; 424/192.100; 435/069.100; 435/252.300;  
 435/320.100; 435/325.000; 514/012.000; 514/023.000; 530/350.000;  
 530/402.000; 530/815.000; 536/023.500  
 IC [7]  
 ICM C12P021-02  
 ICS C12N005-06; C07H021-04; C07K014-715  
 IPCI C12P0021-02 [ICM,7]; C12N0005-06 [ICS,7]; C07H0021-04 [ICS,7];  
 C07H0021-00 [ICS,7,C\*]; C07K0014-715 [ICS,7]; C07K0014-435  
 [ICS,7,C\*]  
 IPCI-2 A61K0038-17 [I,A]; C07K0014-705 [I,A]; C07K0014-435 [I,C\*]  
 IPCR A01K0067-027 [I,A]; A01K0067-027 [I,C\*]; A61K0038-00 [N,A];  
 A61K0038-00 [N,C\*]; A61K0047-48 [I,A]; A61K0047-48 [I,C\*];  
 C07K0014-435 [I,C\*]; C07K0014-705 [I,A]; C07K0014-715 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 34 OF 43 USPATFULL on STN  
 AN 2002:221782 USPATFULL  
 TI Combination therapy using a TNF binding protein for treating  
 TNF-mediated diseases  
 IN Bendele, Alison M., Nederland, CO, UNITED STATES  
 Sennello, Regina M., Boulder, CO, UNITED STATES  
 Edwards, Carl K., III, Thousand Oaks, CA, UNITED STATES  
 PA Amgen Inc. (U.S. corporation)  
 PI US 2002119924 A1 20020829  
 AI US 2001-907263 A1 20010717 (9)  
 RLI Division of Ser. No. US 1999-326394, filed on 4 Jun 1999, PATENTED  
 Continuation of Ser. No. WO 1997-US22733, filed on 8 Dec 1997, UNKNOWN  
 PRAI US 1996-32587P 19961206 (60)  
 US 1997-36355P 19970123 (60)  
 US 1997-39315P 19970207 (60)  
 US 1997-52023P 19970709 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2589  
 INCL INCLM: 514/012.000  
 INCLS: 424/145.100; 514/251.000  
 NCL NCLM: 514/012.000  
 NCLS: 424/145.100; 514/251.000  
 IC [7]  
 ICM A61K039-395  
 ICS A61K031-525; A61K038-17  
 IPCI A61K0039-395 [ICM,7]; A61K0031-525 [ICS,7]; A61K0031-519  
 [ICS,7,C\*]; A61K0038-17 [ICS,7]  
 IPCR A61K0038-17 [I,A]; A61K0038-17 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 35 OF 43 USPATFULL on STN

AN 2001:185255 USPATFULL  
 TI Combination therapy using a TNF binding protein for treating  
 TNF-mediated diseases  
 IN Bendele, Alison M., Nederland, CO, United States  
 Sennello, Regina M., Boulder, CO, United States  
 Edwards III, Carl K., Thousand Oaks, CA, United States  
 PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)  
 PI US 6306820 B1 20011023  
 AI US 1999-326394 19990604 (9)  
 RLI Continuation of Ser. No. WO 1997-US22733, filed on 8 Dec 1997  
 PRAI US 1996-32587P 19961206 (60)  
 US 1997-36355P 19970123 (60)  
 US 1997-39315P 19970207 (60)  
 US 1997-52023P 19970709 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2664  
 INCL INCLM: 514/002.000  
 INCLS: 530/350.000  
 NCL NCLM: 514/002.000  
 NCLS: 530/350.000  
 IC [7]  
 ICM A61K038-17  
 IPCI A61K0038-17 [ICM,7]  
 IPCR A61K0038-17 [I,A]; A61K0038-17 [I,C\*]  
 EXF 514/2; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 36 OF 43 USPATFULL on STN  
 AN 1999:63097 USPATFULL  
 TI Antigenic modulation of cells  
 IN Scott, Mark D., Clifton Park, NY, United States  
 Eaton, John W., Houston, TX, United States  
 PA Albany Medical College, Albany, NY, United States (U.S. corporation)  
 PI US 5908624 19990601  
 AI US 1996-671452 19960627 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 833  
 INCL INCLM: 424/093.700  
 INCLS: 424/093.100; 424/184.100; 435/325.000; 435/382.000; 435/177.000;  
 435/178.000; 435/181.000; 435/001.100  
 NCL NCLM: 424/093.700  
 NCLS: 424/093.100; 424/184.100; 435/001.100; 435/177.000; 435/178.000;  
 435/181.000; 435/325.000; 435/382.000  
 IC [6]  
 ICM A61K035-12  
 ICS A61K035-39; C12N005-00  
 IPCI A61K0035-12 [ICM,6]; A61K0035-39 [ICS,6]; A61K0035-37 [ICS,6,C\*];  
 C12N0005-00 [ICS,6]  
 IPCR A61K0035-12 [N,A]; A61K0035-12 [N,C\*]; A61K0035-18 [I,A];  
 A61K0035-18 [I,C\*]; A61K0039-00 [I,A]; A61K0039-00 [I,C\*];  
 C12N0005-06 [I,A]; C12N0005-06 [I,C\*]  
 EXF 424/93.7; 424/93.1; 424/184.1; 435/325; 435/382; 435/177; 435/178;  
 435/181; 435/1.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 37 OF 43 USPATFULL on STN  
 AN 1998:98599 USPATFULL  
 TI Mono-pegylated proteins that stimulate megakaryocyte growth and  
 differentiation  
 IN Bartley, Timothy D., Thousand Oaks, CA, United States  
 Bogenberger, Jakob M., Camarillo, CA, United States  
 Bosselman, Robert A., Thousand Oaks, CA, United States

Hunt, Pamela, Thousand Oaks, CA, United States  
 Kinstler, Olaf B., Oxnard, CA, United States  
 Samal, Babru B., Moorpark, CA, United States  
 PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)  
 PI US 5795569 19980818  
 AI US 1994-321488 19941012 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-252628, filed on 31 May 1994  
 which is a continuation-in-part of Ser. No. US 1994-221768, filed on 31  
 Mar 1994, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 3489  
 INCL INCLM: 424/085.100  
 INCLS: 530/402.000; 530/351.000; 435/069.500; 930/140.000  
 NCL NCLM: 424/085.100  
 NCLS: 435/069.500; 530/351.000; 530/402.000; 930/140.000  
 IC [6]  
 ICM C07K001-113  
 ICS C07K014-52; A61K038-19  
 IPCI C07K0001-113 [ICM,6]; C07K0001-00 [ICM,6,C\*]; C07K0014-52  
 [ICS,6]; C07K0014-435 [ICS,6,C\*]; A61K0038-19 [ICS,6]  
 IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; C07K0014-435 [I,C\*];  
 C07K0014-52 [I,A]; C07K0017-00 [I,C\*]; C07K0017-08 [I,A]  
 EXF 530/351; 530/402; 536/23.5; 424/85.1; 424/195.1; 424/195.11; 435/69.5;  
 435/188; 930/140  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 38 OF 43 USPATFULL on STN  
 AN 1998:68515 USPATFULL  
 TI Method for treating mammals with monopegylated proteins that stimulates  
 megakaryocyte growth and differentiation  
 IN Bartley, Timothy D., Thousand Oaks, CA, United States  
 Bogenberger, Jakob M., Camarillo, CA, United States  
 Bosselman, Robert A., Thousand Oaks, CA, United States  
 Hunt, Pamela, Thousand Oaks, CA, United States  
 Kinstler, Olaf B., Thousand Oaks, CA, United States  
 Samal, Babru B., Moorpark, CA, United States  
 PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)  
 PI US 5766581 19980616  
 AI US 1995-413803 19950330 (8)  
 RLI Continuation of Ser. No. US 1994-347780, filed on 30 Nov 1994 which is a  
 continuation-in-part of Ser. No. US 1994-321488, filed on 12 Oct 1994  
 which is a continuation-in-part of Ser. No. US 1994-252628, filed on 31  
 May 1994 which is a continuation-in-part of Ser. No. US 1994-221768,  
 filed on 31 Mar 1994, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 3949  
 INCL INCLM: 424/085.100  
 INCLS: 530/351.000; 530/402.000; 930/140.000; 435/069.500  
 NCL NCLM: 424/085.100  
 NCLS: 435/069.500; 530/351.000; 530/402.000; 930/140.000  
 IC [6]  
 ICM A61K038-19  
 ICS C07K001-113; C07K014-52  
 IPCI A61K0038-19 [ICM,6]; C07K0001-113 [ICS,6]; C07K0001-00  
 [ICS,6,C\*]; C07K0014-52 [ICS,6]; C07K0014-435 [ICS,6,C\*]  
 IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; A61K0047-48 [I,A];  
 A61K0047-48 [I,C\*]; C07K0014-435 [I,C\*]; C07K0014-52 [I,A];  
 C07K0017-00 [I,C\*]; C07K0017-08 [I,A]  
 EXF 530/351; 530/402; 536/23.5; 536/85.1; 536/195.1; 536/195.11; 435/69.5;  
 435/188; 930/140  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 39 OF 43 USPATFULL on STN  
 AN 93:8678 USPATFULL  
 TI Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides  
 IN Ikeda, Yoshiharu, Somerville, MA, United States  
 Kai, Yoshiyuki, Kobe, Japan  
 Ono, Keiichi, Sakai, Japan  
 PA Sumitomo Pharmaceuticals Company, Limited, Osaka, Japan (non-U.S. corporation)  
 PI US 5183660 19930202  
 AI US 1991-745496 19910815 (7)  
 PRAI JP 1990-227541 19900828  
 DT Utility  
 FS Granted  
 LN.CNT 931  
 INCL INCLM: 424/094.300  
 INCLS: 435/188.000; 514/002.000; 514/012.000; 530/345.000; 530/399.000; 530/406.000; 530/410.000; 562/465.000; 562/473.000  
 NCL NCLM: 424/094.300  
 NCLS: 435/188.000; 514/002.000; 514/012.000; 530/345.000; 530/399.000; 530/406.000; 530/410.000; 562/465.000; 562/473.000  
 IC [5]  
 ICM A61K037-02  
 ICS A61K037-48; C07C063-04; C07C065-21  
 IPCI A61K0037-02 [ICM,5]; A61K0037-48 [ICS,5]; C07C0063-04 [ICS,5]; C07C0063-00 [ICS,5,C\*]; C07C0065-21 [ICS,5]; C07C0065-00 [ICS,5,C\*]  
 IPCR A61K0047-48 [I,A]; A61K0047-48 [I,C\*]; C08G0065-00 [I,C\*]; C08G0065-331 [I,A]; C08G0065-332 [I,A]  
 EXF 530/345; 530/389; 530/406; 530/410; 530/307; 530/399; 530/391.1; 568/629; 568/630; 568/648; 562/465; 562/473; 562/493; 562/496; 528/425; 514/2; 514/12; 424/94.4; 424/94.64; 424/94.3; 435/177; 435/188  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 43 USPATFULL on STN  
 AN 92:34276 USPATFULL  
 TI Reduction of chemically modified proteins  
 IN Ueno, Hayao, Suita, Japan  
 Fujino, Masahiko, Takarazuka, Japan  
 PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
 PI US 5109120 19920428  
 AI US 1989-364707 19890609 (7)  
 RLI Division of Ser. No. US 1987-21768, filed on 4 Mar 1987, now abandoned  
 PRAI JP 1986-53061 19860310  
 DT Utility  
 FS Granted  
 LN.CNT 556  
 INCL INCLM: 530/351.000  
 INCLS: 530/300.000; 530/303.000; 530/324.000; 530/345.000; 530/350.000; 530/387.100; 530/399.000; 530/402.000; 530/403.000; 530/391.100; 435/188.000  
 NCL NCLM: 530/351.000  
 NCLS: 435/188.000; 530/300.000; 530/303.000; 530/324.000; 530/345.000; 530/350.000; 530/387.100; 530/391.100; 530/399.000; 530/402.000; 530/405.000  
 IC [5]  
 ICM C07K001-00  
 ICS C07K001-06; C07K017-00; C12N011-00  
 IPCI C07K0001-00 [ICM,5]; C07K0001-06 [ICS,5]; C07K0001-00 [ICS,5,C\*]; C07K0017-00 [ICS,5]; C12N0011-00 [ICS,5]  
 IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; C07K0001-00 [I,C\*]; C07K0001-107 [I,A]; C07K0014-435 [I,C\*]; C07K0014-55 [I,A]; C07K0014-555 [I,A]; C07K0014-56 [I,A]  
 EXF 530/405; 530/409; 530/351; 530/815; 530/402; 530/403; 530/300; 530/345;

530/350; 530/391; 530/399; 530/303; 530/324; 530/387; 530/389; 435/188  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 41 OF 43 USPAT2 on STN  
AN 2004:221771 USPAT2  
TI Pegylated T1249 polypeptide  
IN Bailon, Pascal S., Florham Park, NJ, UNITED STATES  
Won, Chee-Youb, Livingston, NJ, UNITED STATES  
PA Hoffmann-La Roche Inc., Nutley, NJ, UNITED STATES (U.S. corporation)  
PI US 7084261 B2 20060801  
AI US 2003-625103 20030722 (10)  
PRAI US 2003-439213P 20030110 (60)  
US 2002-398190P 20020724 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1465  
INCL INCLM: 530/402.000  
INCLS: 530/324.000  
NCL NCLM: 530/402.000; 514/012.000  
NCLS: 530/324.000; 530/409.000  
IC IPCI A61K0038-17 [ICM,7]; C07K0014-705 [ICS,7]; C07K0014-435  
[ICS,7,C\*]  
IPCI-2 A61K0038-12 [I,A]; C08H0001-00 [I,A]  
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; A61K0047-48 [I,A];  
A61K0047-48 [I,C\*]; C07K0014-005 [I,C\*]; C07K0014-155 [I,A]  
EXF 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 42 OF 43 USPAT2 on STN  
AN 2004:64499 USPAT2  
TI Pegylated T20 polypeptide  
IN Bailon, Pascal Sebastian, Florham Park, NJ, UNITED STATES  
Won, Chee-Youb, Livingston, NJ, UNITED STATES  
PA Hoffmann-La Roche Inc., Nutley, NJ, UNITED STATES (U.S. corporation)  
PI US 7049415 B2 20060523  
AI US 2003-623873 20030721 (10)  
PRAI US 2002-398195P 20020724 (60)  
DT Utility  
FS GRANTED  
LN.CNT 937  
INCL INCLM: 530/402.000  
INCLS: 530/324.000  
NCL NCLM: 530/402.000  
NCLS: 530/324.000; 525/054.100; 530/409.000  
IC IPCI C07K0014-47 [ICM,7]; C07K0014-435 [ICM,7,C\*]  
IPCI-2 A61K0038-12 [I,A]; C08H0001-00 [I,A]  
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; C07K0014-005 [I,C\*];  
C07K0014-16 [I,A]  
EXF 530/402  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 43 OF 43 USPAT2 on STN  
AN 2003:78519 USPAT2  
TI Truncated soluble tumor necrosis factor type-I and type-II receptors  
IN Fisher, Eric F., New Braunfels, TX, UNITED STATES  
Edwards, III, Carl K., Superior, CO, UNITED STATES  
Kieft, Gary L., Boulder, CO, UNITED STATES  
PA Amgen Inc., Thousand Oaks, CA, UNITED STATES (U.S. corporation)  
PI US 6989147 B2 20060124  
AI US 2001-882735 20010615 (9)  
RLI Continuation of Ser. No. US 214613, ABANDONED A 371 of International  
Ser. No. WO 1997-US12244, filed on 19 Jul 1997  
PRAI US 1997-39792P 19970304 (60)  
US 1997-37737P 19970123 (60)

	US 1996-32534P	19961206 (60)
	US 1996-621443P	19960709 (60)
	US 39314P	(60)
DT	Utility	
FS	GRANTED	
LN.CNT	5150	
INCL	INCLM: 424/185.100	
	INCLS: 424/134.100; 424/178.100; 424/192.100; 530/350.000; 530/402.000;	
	530/815.000; 514/012.000; 514/023.000; 536/023.500; 435/320.100;	
	435/069.100; 435/325.000; 435/252.300	
NCL	NCLM: 424/185.100; 435/069.100	
	NCLS: 424/134.100; 424/178.100; 424/192.100; 435/069.100; 435/252.300;	
	435/320.100; 435/325.000; 514/012.000; 514/023.000; 530/350.000;	
	530/402.000; 530/815.000; 536/023.500	
IC	IPCI	C12P0021-02 [ICM,7]; C12N0005-06 [ICS,7]; C07H0021-04 [ICS,7];
		C07H0021-00 [ICS,7,C*]; C07K0014-715 [ICS,7]; C07K0014-435
		[ICS,7,C*]
	IPCI-2	A61K0038-17 [I,A]; C07K0014-705 [I,A]; C07K0014-435 [I,C*]
	IPCR	A01K0067-027 [I,A]; A01K0067-027 [I,C*]; A61K0038-00 [N,A];
		A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*];
		C07K0014-435 [I,C*]; C07K0014-705 [I,A]; C07K0014-715 [I,A]
EXF	424/185.1; 424/134.1; 424/178.1; 424/192.1; 530/350; 530/402; 530/815;	
	514/12; 514/23; 536/23.5; 435/320.1; 435/69.1; 435/325; 435/252.3	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=>